Cargando…

A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

BACKGROUND: Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity to zoledronic acid > 200-fold, determined by the half-maximal inhibitory conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Qihua, Møller, Anaïs Marie Julie, Qiu, Chuan, Madsen, Jonna Skov, Shen, Hui, Bechmann, Troels, Delaisse, Jean-Marie, Kristensen, Bjarne Winther, Deng, Hong-Wen, Karasik, David, Søe, Kent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012449/ https://www.ncbi.nlm.nih.gov/pubmed/36915112 http://dx.doi.org/10.1186/s13148-023-01449-1

Ejemplares similares

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
por: Møller, Anaïs M J, et al.
Publicado: (2020)

Aging and menopause reprogram osteoclast precursors for aggressive bone resorption
por: Møller, Anaïs Marie Julie, et al.
Publicado: (2020)

Osteoclast Fusion: Time‐Lapse Reveals Involvement of CD47 and Syncytin‐1 at Different Stages of Nuclearity
por: Møller, Anaïs Marie Julie, et al.
Publicado: (2016)

Fusion Potential of Human Osteoclasts In Vitro Reflects Age, Menopause, and In Vivo Bone Resorption Levels of Their Donors—A Possible Involvement of DC-STAMP
por: Møller, Anaïs M. J., et al.
Publicado: (2020)

Time-lapse reveals that osteoclasts can move across the bone surface while resorbing
por: Søe, Kent, et al.
Publicado: (2017)

Osteoclast Fusion is Based on Heterogeneity Between Fusion Partners
por: Hobolt-Pedersen, Anne-Sofie, et al.
Publicado: (2014)

Pit- and trench-forming osteoclasts: a distinction that matters
por: Merrild, Ditte MH, et al.
Publicado: (2015)

Septins are critical regulators of osteoclastic bone resorption
por: Møller, Anaïs M. J., et al.
Publicado: (2018)

The Mechanism Switching the Osteoclast From Short to Long Duration Bone Resorption
por: Delaisse, Jean-Marie, et al.
Publicado: (2021)

Osteoclasts’ Ability to Generate Trenches Rather Than Pits Depends on High Levels of Active Cathepsin K and Efficient Clearance of Resorption Products
por: Borggaard, Xenia G., et al.
Publicado: (2020)

Potential of Resveratrol Analogues as Antagonists of Osteoclasts and Promoters of Osteoblasts
por: Kupisiewicz, Katarzyna, et al.
Publicado: (2010)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

Minimally effective concentration of zoledronic acid to suppress osteoclasts in vitro
por: Li, Pengfei, et al.
Publicado: (2018)

Predicting brain metastases of breast cancer based on serum S100B and serum HER2
por: BECHMANN, TROELS, et al.
Publicado: (2013)

The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate
por: Ricchiuto, Silvia, et al.
Publicado: (2023)

Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer
por: Kjær, Ina Mathilde, et al.
Publicado: (2020)

Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study
por: Kjær, Ina Mathilde, et al.
Publicado: (2020)

Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells
por: Tai, Ta-Wei, et al.
Publicado: (2017)

Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity—Potential Implications for Drug Sensitivity
por: Søe, Kent
Publicado: (2020)

Spatial Organization of Osteoclastic Coupling Factors and Their Receptors at Human Bone Remodeling Sites
por: Borggaard, Xenia G., et al.
Publicado: (2022)

Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis
por: Kim, Hyung Joon, et al.
Publicado: (2019)

Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB
por: Gao, Si-yong, et al.
Publicado: (2017)

The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits
por: Jensen, Pia Rosgaard, et al.
Publicado: (2013)

Inhibition Effect of Zoledronate on the Osteoclast Differentiation of RAW264.7 Induced by Titanium Particles
por: Zhao, Wenhan, et al.
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
por: Kjær, Ina Mathilde, et al.
Publicado: (2023)

Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice
por: Vegger, Jens Bay, et al.
Publicado: (2018)

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
por: Wang, Lianwei, et al.
Publicado: (2020)

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro
por: Lund, Thomas, et al.
Publicado: (2010)

Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation
por: Qu, Xingzhou, et al.
Publicado: (2021)

Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways
por: Huang, Xiao-Lin, et al.
Publicado: (2019)

Correlation of the methylomic signature of smoking during pregnancy with clinical traits in ADHD
por: Chaumette, Boris, et al.
Publicado: (2023)

Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones
por: Engsig, Michael T., et al.
Publicado: (2000)

Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity
por: Nørregaard, Kirstine Sandal, et al.
Publicado: (2021)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

DNA methylome profiling of all-cause mortality in comparison with age-associated methylation patterns
por: Lund, Jesper Beltoft, et al.
Publicado: (2019)

Mining the Methylome Reveals Extensive Diversity in Staphylococcus epidermidis Restriction Modification
por: Lee, Jean Y. H., et al.
Publicado: (2019)

Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
por: Vimalathas, Gayaththri, et al.
Publicado: (2021)

Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of “Giant Osteoclasts” and Pathogenetic Implications
por: Corsi, Alessandro, et al.
Publicado: (2020)

SUN-347 Glucagon-like Peptide 1 (GLP-1) Acts Directly On Human Osteoclasts To Increase Differentiation And Bone Resorptive Activity
por: Hansen, Morten Steen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9h0i7apo6qvt3egkaj5mqv7nst